Skip to content

Released May 7, 2015, after the close

10-Q filed May 7, 2015, 37 days after period end · 0001144204-15-028431

Q1 2015 · 10-Q
Revenue$1.69M−74.7% vs Q1 2014no prior Q4 2014 on file
Net Income-$5.97MN/M vs Q1 2014N/M vs Q4 2014
EPS Diluted-$0.06N/M vs Q1 2014no prior Q4 2014 on file
Gross Profit$1,410,000−57.4%
Operating Income-$5,384,000N/M
Operating Cash Flow-$6,421,000N/M
Free Cash Flowderived-$6,520,000N/M
Margins · derived
Gross margin83.3%+33.9 pt vs Q1 2014
Operating margin-318.2%−221.6 pt vs Q1 2014
Net margin-353.0%−243.3 pt vs Q1 2014

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2015Q1 2014Q1 2013Q1 2012
Revenue$1.69M$6.70M$3.57M$3.86M
Net Income-$5.97M-$7.35M-$4.32M-$5.90M
EPS Diluted-$0.06$0.08$0.05$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR